NASDAQ:GILD
Gilead Stock News
$73.01
+0.600 (+0.83%)
At Close: Mar 27, 2024
Time for Gilead Sciences-Heavy ETFs?
03:05pm, Tuesday, 12'th Sep 2023
Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
12:46pm, Monday, 11'th Sep 2023
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.
3 Dividend Stocks for September 2023
12:00pm, Saturday, 09'th Sep 2023
#Morningstar #PfizerStock #DividendStocks Dividend investors: Put these cheap stocks on your buy list. 00:00 Introduction 00:28 Pfizer PFE 01:03 Medtronic MDT 01:34 Gilead Sciences GILD Susan Dziub
Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans
03:17am, Saturday, 09'th Sep 2023
Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained stable
Bank of America says buy Gilead
02:31pm, Friday, 08'th Sep 2023
The "Halftime Report" traders debate the biggest analyst calls of the day.
Gilead Stock Looks Underappreciated and Oversold, Say BofA Analysts
11:20am, Friday, 08'th Sep 2023
BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.
Gilead Sciences, Inc. (GILD) Wells Fargo Healthcare Conference - (Transcript)
03:21pm, Wednesday, 06'th Sep 2023
Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo Healthcare Conference September 6, 2023 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit
Call of the day: The health care trade
01:30pm, Wednesday, 06'th Sep 2023
CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.
Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
02:40pm, Tuesday, 29'th Aug 2023
Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and a l
Nearing Retirement? These Stocks Will Pay You For Life
09:45am, Tuesday, 29'th Aug 2023
Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
01:32pm, Friday, 25'th Aug 2023
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
GILD Stock Alert: FDA Approves Gilead Sciences' Veklury Covid-19 Treatment
11:39am, Thursday, 24'th Aug 2023
Gilead Sciences (NASDAQ: GILD ) stock is on the move Thursday following FDA approval for its Veklury Covid-19 treatment. This saw the FDA approve the company's supplemental new drug application (sNDA)
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Wednesday, 23'rd Aug 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Co
Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data
08:45am, Wednesday, 23'rd Aug 2023
Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
01:32pm, Tuesday, 22'nd Aug 2023
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.